GlassScriptPhysician profile
Ashleigh E Tharp
NPI 1093392201
$1,847.37
in general payments reported to CMS, 2019-2025
27 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $561 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $329.25 | 2024-2025 | |
| Glaxosmithkline, LLC. | $176.41 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $175.96 | 2024-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $153.66 | 2024-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $153.58 | 2024-2025 | |
| Lilly USA, LLC | $117.00 | 2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $105.06 | 2024-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $91.03 | 2025 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $55.58 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.88 | 2024 | Jardiance, Ofev |
| Sanofi-Aventis U.S. LLC | $50.04 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $46.90 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $42.25 | 2024 | Eohilia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.77 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $34.23 | 2024 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $23.47 | 2024 | |
| Argenx US, INC. | $22.20 | 2025 | Vyvgart |
| Kyowa Kirin, INC. | $21.53 | 2025 | |
| Boston Scientific Corporation | $19.70 | 2024 | Watchman Flx |
| Sanofi Pasteur INC. | $19.40 | 2025 | |
| Ardelyx, INC. | $19.12 | 2025 | Ibsrela |
| Noven Therapeutics, LLC | $18.00 | 2024 | Xelstrym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.78 | 2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $16.30 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $15.88 | 2025 | Inspire |
| Lundbeck LLC | $14.83 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $13.56 | 2025 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashleigh Tharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.